

Product Update:

cholecalciferol 25,000 international units oral solution (InVita D3®)
SMC No. (1011/14)

Consilient Health Limited

07 November 2014

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

cholecalciferol oral solution (InVita D3®) is accepted for use within NHS Scotland.

Indication under review: the prevention and treatment of vitamin D deficiency.

As an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.

The therapeutic use and safety profile of cholecalciferol as a treatment for vitamin D deficiency and as an adjunctive treatment in osteoporosis is well established. InVita D3® provides a higher strength preparation than some other licensed vitamin D preparations and is licensed for use in both children and adults. At equivalent doses, it is a similar cost to other vitamin D preparations. InVitaD3® is listed in the British National Formulary for Children 2014-2015.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 18 September 2014.

Chairman
Scottish Medicines Consortium